Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
ConclusionsStandard-dose alteplase treatment reduced the risk of long-term recurrence of AIS after hospital discharge and the alteplase dose was not associated with the long-term risk of death from AIS.
Source: Neurology and Therapy - Category: Neurology Source Type: research
More News: Activase | Atrial Fibrillation | Brain | Ischemic Stroke | Neurology | Stroke | Study | Thrombosis